You are here: Industry Insights > Tecartus

News List

Gilead Revenues up 16% in the Quarter contractpharma
May 06, 2021
Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.
Gilead Revenues up 16% in the Quarter contractpharma
May 06, 2021
Veklury drives growth in the quarter, offsetting significant declines in HIV, HCV franchises.
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma europeanpharmaceuticalreview
January 26, 2021
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
Tecartus wins NICE recommendation for mantle cell lymphoma pharmatimes
January 20, 2021
The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma ...
Gilead's CAR T therapy Tecartus authorised in EU for MCL pharmatimes
December 18, 2020
Gilead’s Kite division has announced that its chimericantigen receptor (CAR) T cell therapy Tecartus has received conditional marketing authorisation for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
EMA recommends 10 medicines for approval in October meeting europeanpharmaceuticalreview
October 23, 2020
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Ten new medicines backed for EU approval pharmatimes
October 21, 2020
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended ten new medicines for approval at its October 2020 meeting.
FDA approves Tecartus, cell-based gene therapy to treat relapsed or refractory MCL in adults expresspharma
July 27, 2020
It also received ‘Orphan Drug’ designation, which provides incentives to assist and encourage the development of drugs for rare diseases.